Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.376
S. Barbadillo, V. Martínez Callejo, M. Ochagavía Sufrategui, A. García-Avello Fernández-Cueto, MV Villacañas Palomares, VS Carmen Maria, M. Martín López, M. Valero Domínguez
{"title":"2SPD-003 Telepharmacy in onco-haematologic patients: a 7-month experience","authors":"S. Barbadillo, V. Martínez Callejo, M. Ochagavía Sufrategui, A. García-Avello Fernández-Cueto, MV Villacañas Palomares, VS Carmen Maria, M. Martín López, M. Valero Domínguez","doi":"10.1136/ejhpharm-2022-eahp.376","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.376","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116040462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.400
L. Perez Cordon, A. Sánchez Ulayar, S. Marín Rubio, V. Aguilera Jimenez, L. Campins Bernadàs, J. Delgado Rodríguez, M. Bitlloch Obiols, R. Merino Méndez, T. Gurrera Roig, D. López Faixó
{"title":"4CPS-164 Durability of oral dual antiretroviral therapy in HIV patients","authors":"L. Perez Cordon, A. Sánchez Ulayar, S. Marín Rubio, V. Aguilera Jimenez, L. Campins Bernadàs, J. Delgado Rodríguez, M. Bitlloch Obiols, R. Merino Méndez, T. Gurrera Roig, D. López Faixó","doi":"10.1136/ejhpharm-2022-eahp.400","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.400","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115318634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.377
R. Tamayo Bermejo, JC del Río Valencia, B. Mora Rodríguez, I. Muñoz Castillo
{"title":"2SPD-012 Immunotherapy in patients with non-small cell lung cancer: effectiveness and safety in real life","authors":"R. Tamayo Bermejo, JC del Río Valencia, B. Mora Rodríguez, I. Muñoz Castillo","doi":"10.1136/ejhpharm-2022-eahp.377","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.377","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131214907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.413
J. Pedreira Bouzas, EM García Rebolledo, C. Puivecino Moreno, M. García Gil
Background and importance Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a poor prognosis. Nintedanib and pirfenidone are the only drugs indicated for this path-ology. In pivotal clinical trials these drugs reduced the decline in forced vital capacity (FVC), which is consistent with a slowing of disease progression. and objectives Evaluation of the effectiveness and safety of nintedanib and pirfenidone in IPF in a second-level hospital.
{"title":"4CPS-257 Effectiveness and safety of nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis","authors":"J. Pedreira Bouzas, EM García Rebolledo, C. Puivecino Moreno, M. García Gil","doi":"10.1136/ejhpharm-2022-eahp.413","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.413","url":null,"abstract":"Background and importance Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a poor prognosis. Nintedanib and pirfenidone are the only drugs indicated for this path-ology. In pivotal clinical trials these drugs reduced the decline in forced vital capacity (FVC), which is consistent with a slowing of disease progression. and objectives Evaluation of the effectiveness and safety of nintedanib and pirfenidone in IPF in a second-level hospital.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"119 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131419359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.398
A. Aguado Paredes, M. Romero González, J. Cordero Ramos, M. Beltrán García
{"title":"4CPS-140 Antimicrobial stewardship programme in oncology patients through a multidisciplinary team","authors":"A. Aguado Paredes, M. Romero González, J. Cordero Ramos, M. Beltrán García","doi":"10.1136/ejhpharm-2022-eahp.398","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.398","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133128442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.383
R. Tamayo Bermejo, JC del Río Valencia, B. Mora Rodríguez, I. Muñoz Castillo
{"title":"4CPS-029 Pembrolizumab, nivolumab and atezolizumab: incremental cost-effectiveness ratio","authors":"R. Tamayo Bermejo, JC del Río Valencia, B. Mora Rodríguez, I. Muñoz Castillo","doi":"10.1136/ejhpharm-2022-eahp.383","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.383","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"301 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124297759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：